In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 

Automated quantification of epicardial adipose tissue from non-contrast CT on multi-center and multi-vendor data using deep learning

Session Advanced PET & CT techniques for clinical practice

Speaker Frederic Commandeur

Congress : ESC Congress 2019

  • Topic : imaging
  • Sub-topic : Coronary Calcium Score
  • Session type : Abstract Session
  • FP Number : 5963

Authors : F Commandeur (Los Angeles,US), M Goeller (Erlangen,DE), A Razipour (Los Angeles,US), S Cadet (Los Angeles,US), MM Hell (Erlangen,DE), J Kwiecinski (Los Angeles,US), X Chen (Los Angeles,US), HJ Chang (Seoul,KR), M Marwan (Erlangen,DE), S Achenbach (Erlangen,DE), DS Berman (Los Angeles,US), PJ Slomka (Los Angeles,US), BK Tamarappoo (Los Angeles,US), D Dey (Los Angeles,US)

Authors:
F Commandeur1 , M Goeller2 , A Razipour1 , S Cadet3 , MM Hell2 , J Kwiecinski3 , X Chen3 , HJ Chang4 , M Marwan2 , S Achenbach2 , DS Berman3 , PJ Slomka3 , BK Tamarappoo3 , D Dey1 , 1Cedars-Sinai Medical Center, Biomedical Imaging Research Institute - Los Angeles - United States of America , 2Friedrich Alexander University, Department of Cardiology - Erlangen - Germany , 3Cedars-Sinai Medical Center, Department of Imaging and Medicine - Los Angeles - United States of America , 4Severance Hospital, Yonsei University College of Medicine - Seoul - Korea (Republic of) ,

Citation:

Background
Epicardial adipose tissue (EAT), a metabolically active visceral fat depot surrounding the coronary arteries, has been shown to promote the development of atherosclerosis in underlying coronary vasculature.

Purpose
We evaluate the performance of deep learning (DL), a sub-group of machine learning algorithms, for robust and fully automated quantification of EAT on multi-center cardiac CT data.

Methods
In this study, 850 non-contrast calcium scoring CT scans, from multiple cohorts, scanners and protocols, with manual measurements of EAT from 3 different readers were considered. The DL method was based on a convolutional neural network trained to reproduce the expert measurement. DL global performance was first assessed using all the scans, and then compared to inter-observer variability on a subset of 141 scans. Finally, automated EAT progression was compared to manual measurement using baseline and follow-up serial scans available for 70 subjects. The proposed model was validated using 10-fold cross validation.

Results
Automated quantification was performed in 1.57+-0.49 seconds compared to 15 minutes for manual measurement. DL provided high agreement with expert manual quantification for all scans (R=0.974, p<0.001) with no significant bias (0.53 cm3, p=0.13). EAT volume was higher in patients with hypertension (+18.02 cm3, p<0.001, N=442), with diabetes (+18.33 cm3, p<0.001, N=75) and with hypercholesterolemia (+7.33 cm3, p=0.039, N=508). Manual EAT volumes measured by two experienced readers on 141 scans were highly correlated (R=0.984, p<0.001) but presented a significant difference of 4.35 cm3 (p<0.001). On these 141 scans, DL quantifications were highly correlated to both experts’ measurements (R=0.973, p<0.001; R=0.979, p<0.001) with significant and non-significant bias for readers 1 and 2 (5.19 cm3, p<0.001; 0.84 cm3, p=0.26), respectively. In 70 subjects, EAT progression quantified by DL correlated strongly with EAT progression measured by the expert reader (R=0.905, p<0.001) with no significant bias (0.64 cm3, p=0.43), and was related to increased non-calcified plaque burden quantified from coronary CT angiography (5.7% vs 1.8%, p=0.026).

Conclusion
Deep learning allows rapid, robust and fully automated quantification of EAT from calcium scoring CT. It performs as an expert reader and can be implemented for routine cardiovascular risk assessment.

This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are